Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 51
- −8 vs. Q2 2024
- Portfolio value
- $293.2M
- +$5.86M (+2.0%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 325,000 | $1.05M | 0.4% | +325,000 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 160,898 | $1.06M | 0.4% | −259,433−61.7% | Reduced | History |
| LRMRLarimar Therapeutics, Inc. | COM | 200,000 | $1.31M | 0.4% | +200,000 | New | History |
| ATYRaTYR PHARMA INC | COM NEW | 800,000 | $1.41M | 0.5% | 00.0% | Unchanged | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 887,700 | $1.62M | 0.6% | −12,300−1.4% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 75,000 | $1.71M | 0.6% | −512,708−87.2% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 60,000 | $1.76M | 0.6% | −190,237−76.0% | Reduced | History |
| SMMTSummit Therapeutics Inc. | COM | 85,000 | $1.86M | 0.6% | +85,000 | New | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 65,000 | $1.87M | 0.6% | −70,000−51.9% | Reduced | History |
| CAPRCapricor Therapeutics, Inc. | COM NEW | 125,000 | $1.90M | 0.6% | +125,000 | New | History |
| NGNENeurogene Inc. | COM | 50,000 | $2.10M | 0.7% | −20,000−28.6% | Reduced | History |
| ABSIAbsci Corp | COM | 550,000 | $2.10M | 0.7% | +550,000 | New | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 500,000 | $2.64M | 0.9% | +500,000 | New | History |
| RGNXREGENXBIO Inc. | COM | 265,000 | $2.78M | 0.9% | +95,000+55.9% | Added | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,500,000 | $2.90M | 1.0% | +150,000+11.1% | Added | History |
| SVRASavara Inc | COM | 725,000 | $3.07M | 1.0% | −325,876−31.0% | Reduced | History |
| NUVBNuvation Bio Inc. | COM CL A | 1,350,000 | $3.09M | 1.1% | +200,000+17.4% | Added | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 300,000 | $3.13M | 1.1% | 00.0% | Unchanged | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 160,000 | $3.30M | 1.1% | −15,000−8.6% | Reduced | History |
| ARVNArvinas, Inc. | COM | 145,000 | $3.57M | 1.2% | +70,000+93.3% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 100,000 | $3.59M | 1.2% | +100,000 | New | History |
| KRROKorro Bio, Inc. | COM | 110,000 | $3.68M | 1.3% | +10,000+10.0% | Added | History |
| ANNXAnnexon, Inc. | COM | 650,000 | $3.85M | 1.3% | +340,000+109.7% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 78,842 | $4.13M | 1.4% | −38,546−32.8% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 2,150,000 | $4.32M | 1.5% | +900,000+72.0% | Added | History |
| BBIOBridgeBio Pharma, Inc. | COM | 175,000 | $4.46M | 1.5% | +35,000+25.0% | Added | History |
| REPLReplimune Group, Inc. | COM | 450,000 | $4.93M | 1.7% | 00.0% | Unchanged | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 195,000 | $5.20M | 1.8% | +195,000 | New | History |
| INSMINSMED Inc | COM PAR $.01 | 75,000 | $5.47M | 1.9% | +10,000+15.4% | Added | History |
| IMVTImmunovant, Inc. | COM | 215,000 | $6.13M | 2.1% | −45,000−17.3% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 535,000 | $6.39M | 2.2% | −15,000−2.7% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 128,411 | $6.47M | 2.2% | −171,589−57.2% | Reduced | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 375,000 | $6.78M | 2.3% | −225,000−37.5% | Reduced | History |
| RZLTRezolute, Inc. | COM NEW | 1,474,995 | $7.15M | 2.4% | +53,494+3.8% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 310,000 | $7.25M | 2.5% | −190,000−38.0% | Reduced | History |
| SLNOSoleno Therapeutics Inc | COM | 150,000 | $7.57M | 2.6% | −150,000−50.0% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 150,000 | $7.67M | 2.6% | −90,000−37.5% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 52,500 | $7.84M | 2.7% | −34,221−39.5% | Reduced | History |
| JANXJanux Therapeutics, Inc. | COM | 190,000 | $8.63M | 2.9% | +140,000+280.0% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 450,000 | $8.66M | 3.0% | +100,000+28.6% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 140,000 | $8.86M | 3.0% | +45,000+47.4% | Added | History |
| PCVXVaxcyte, Inc. | COM | 80,000 | $9.14M | 3.1% | −70,000−46.7% | Reduced | History |
| ROIVRoivant Sciences Ltd. | SHS | 800,000 | $9.23M | 3.1% | −200,000−20.0% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 250,000 | $9.43M | 3.2% | −10,000−3.8% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 750,000 | $10.0M | 3.4% | −175,000−18.9% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 350,000 | $11.5M | 3.9% | +115,000+48.9% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 135,000 | $12.1M | 4.1% | −15,000−10.0% | Reduced | History |
| BPMCBlueprint Medicines Corp | COM | 140,000 | $12.9M | 4.4% | +100,000+250.0% | Added | History |
| NVONovo Nordisk A S | ADR | 110,000 | $13.1M | 4.5% | +110,000 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 120,000 | $15.0M | 5.1% | +65,000+118.2% | Added | History |
| Biohaven LtdG1110E907 | CALL | 348,778 | $17.4M | 5.9% | +348,778 | New | – |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2024 (18)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| BHVNBiohaven Ltd. | COM | 490,000 | $17.0M | 5.9% | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 22,500 | $5.47M | 1.9% | History |
| ACADAcadia Pharmaceuticals Inc | COM | 225,000 | $3.66M | 1.3% | History |
| CABACabaletta Bio, Inc. | COM | 370,899 | $2.77M | 1.0% | History |
| CYTKCytokinetics Inc | COM NEW | 33,200 | $1.80M | 0.6% | History |
| ELEVElevation Acquisition Group Inc. | COM | 600,000 | $1.62M | 0.6% | History |
| KRYSKrystal Biotech, Inc. | COM | 8,500 | $1.56M | 0.5% | History |
| WVEWave Life Sciences, Inc. | SHS | 200,000 | $998.0K | 0.3% | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 35,000 | $909.6K | 0.3% | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 225,000 | $769.5K | 0.3% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 10,000 | $684.9K | 0.2% | History |
| MGNXMacrogenics Inc | COM | 150,000 | $637.5K | 0.2% | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 375,000 | $607.5K | 0.2% | History |
| PTCTPTC Therapeutics, Inc. | COM | 19,000 | $581.0K | 0.2% | History |
| RVNCRevance Therapeutics, Inc. | COM | 225,000 | $578.3K | 0.2% | History |
| NTLAIntellia Therapeutics, Inc. | COM | 25,000 | $559.5K | 0.2% | History |
| ANTXAN2 Therapeutics, Inc. | COM | 219,331 | $471.6K | 0.2% | History |
| CTMXCytomX Therapeutics, Inc. | COM | 300,000 | $366.0K | 0.1% | History |